Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 9.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 279,577 shares of the company’s stock after acquiring an additional 23,982 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Y-mAbs Therapeutics were worth $3,676,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Squarepoint Ops LLC lifted its holdings in Y-mAbs Therapeutics by 143.4% during the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after purchasing an additional 74,452 shares in the last quarter. Millennium Management LLC raised its position in shares of Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after purchasing an additional 67,233 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after buying an additional 65,732 shares in the last quarter. XTX Topco Ltd purchased a new position in Y-mAbs Therapeutics in the 2nd quarter valued at about $297,000. Finally, Principal Financial Group Inc. acquired a new stake in Y-mAbs Therapeutics in the 3rd quarter worth about $267,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 30,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the transaction, the insider now directly owns 67,681 shares in the company, valued at approximately $877,822.57. This represents a 30.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 22.50% of the company’s stock.

Y-mAbs Therapeutics Stock Down 3.5 %

Shares of YMAB opened at $9.43 on Friday. Y-mAbs Therapeutics, Inc. has a 52-week low of $6.09 and a 52-week high of $20.90. The stock has a fifty day simple moving average of $12.87 and a two-hundred day simple moving average of $12.68. The company has a market capitalization of $422.37 million, a PE ratio of -17.46 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the previous year, the business posted ($0.18) earnings per share. As a group, equities analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

YMAB has been the subject of a number of research analyst reports. Brookline Capital Management started coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a report on Wednesday. Finally, Oppenheimer started coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $20.89.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.